Abbrea Capital’s Johnson & Johnson JNJ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | $8.64M | Sell |
59,099
-1,848
| -3% | -$275K | 1.14% | 25 |
|
|
2024
Q1 | $9.64M | Sell |
60,947
-2,759
| -4% | -$439K | 1.27% | 21 |
|
|
2023
Q4 | $9.98M | Sell |
63,706
-1,795
| -3% | -$275K | 1.44% | 19 |
|
|
2023
Q3 | $10.2M | Sell |
65,501
-1,675
| -2% | -$276K | 1.62% | 18 |
|
|
2023
Q2 | $11.1M | Buy |
67,176
+207
| +0.3% | +$33.4K | 1.71% | 16 |
|
|
2023
Q1 | $10.4M | Sell |
66,969
-132
| -0.2% | -$21.3K | 1.76% | 13 |
|
|
2022
Q4 | $11.9M | Buy |
67,101
+941
| +1% | +$162K | 2.14% | 8 |
|
|
2022
Q3 | $10.8M | Sell |
66,160
-503
| -0.8% | -$85.1K | 2.04% | 9 |
|
|
2022
Q2 | $11.8M | Sell |
66,663
-239
| -0.4% | -$42.6K | 1.97% | 10 |
|
|
2022
Q1 | $11.9M | Sell |
66,902
-1,187
| -2% | -$202K | 1.66% | 12 |
|
|
2021
Q4 | $11.6M | Buy |
68,089
+1,728
| +3% | +$283K | 1.57% | 13 |
|
|
2021
Q3 | $10.7M | Sell |
66,361
-1,514
| -2% | -$258K | 1.6% | 13 |
|
|
2021
Q2 | $11.2M | Sell |
67,875
-419
| -0.6% | -$69.4K | 1.68% | 13 |
|
|
2021
Q1 | $11.2M | Buy |
68,294
+210
| +0.3% | +$34K | 1.85% | 11 |
|
|
2020
Q4 | $10.7M | Buy |
68,084
+271
| +0.4% | +$40K | 1.92% | 11 |
|
|
2020
Q3 | $10.1M | Sell |
67,813
-379
| -0.6% | -$56.1K | 2.14% | 11 |
|
|
2020
Q2 | $9.59M | Buy |
68,192
+448
| +0.7% | +$65.3K | 2.19% | 10 |
|
|
2020
Q1 | $8.88M | Sell |
67,744
-877
| -1% | -$124K | 2.36% | 9 |
|
|
2019
Q4 | $10M | Buy |
68,621
+461
| +0.7% | +$62.5K | 2.13% | 10 |
|
|
2019
Q3 | $8.82M | Buy |
68,160
+1,698
| +3% | +$224K | 2.04% | 12 |
|
|
2019
Q2 | $9.26M | Buy |
66,462
+31,661
| +91% | +$4.38M | 2.27% | 10 |
|
|
2019
Q1 | $4.87M | Buy |
34,801
+92
| +0.3% | +$12.3K | 1.4% | 17 |
|
|
2018
Q4 | $4.48M | Sell |
34,709
-17
| -0% | -$2.37K | 1.47% | 17 |
|
|
2018
Q3 | $4.8M | Sell |
34,726
-238
| -0.7% | -$31.6K | 1.41% | 16 |
|
|
2018
Q2 | $4.24M | Sell |
34,964
-292
| -0.8% | -$36.4K | 1.33% | 17 |
|
|
2018
Q1 | $4.52M | Buy |
35,256
+1,426
| +4% | +$193K | 1.46% | 16 |
|
|
2017
Q4 | $4.73M | Sell |
33,830
-25
| -0.1% | -$3.48K | 1.61% | 12 |
|
|
2017
Q3 | $4.4M | Buy |
33,855
+441
| +1% | +$58.5K | 1.64% | 12 |
|
|
2017
Q2 | $4.42M | Buy |
33,414
+252
| +0.8% | +$32.1K | 1.76% | 11 |
|
|
2017
Q1 | $4.13M | Buy |
33,162
+1,736
| +6% | +$207K | 1.69% | 13 |
|
|
2016
Q4 | $3.62M | Buy |
+31,426
| New | +$3.63M | 1.7% | 13 |
|
Other funds holding JNJ
Abbrea Capital's JNJ Position: Q2 2024 in Review
Abbrea Capital reduced its Johnson & Johnson (JNJ) stake by 3% in Q2 2024, selling an estimated $275K and leaving 59,099 shares worth $8.64M. The position accounts for 1.14% of the portfolio, ranked #25.
Abbrea Capital first reported a position in JNJ in Q4 2016 and has held it in 31 quarters since. The position peaked at $11.9M in Q1 2022. 3,802 funds tracked by Wall St. Rank hold JNJ as of Q2 2024.
- Abbrea Capital held 59,099 shares of Johnson & Johnson worth $8.64M as of Q2 2024.
- Abbrea Capital sold 1,848 Johnson & Johnson shares in Q2 2024, an estimated $275K.
- Johnson & Johnson made up 1.14% of Abbrea Capital's portfolio in Q2 2024, its #25 holding.
- Abbrea Capital first reported a position in Johnson & Johnson in Q4 2016 and has held it in 31 quarters since.
- Abbrea Capital's Johnson & Johnson position peaked at $11.9M in Q1 2022.
- 3,802 funds tracked by Wall St. Rank held Johnson & Johnson as of Q2 2024.
Based on Abbrea Capital's 13F filing for Q2 2024, filed 8 Aug 2024.